Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment

J Skrzypek1, W Krause

  • 1Department of Dermatology and Allergology, School of Medicine, Philipps University, Marburg, Germany. skrzypek@mailer.uni-marburg.de

Andrologia
|August 24, 2007
PubMed

Insights

Sirolimus, an immunosuppressant, can impair sperm production by affecting the stem cell factor/c-kit pathway. Reversing this effect is possible by switching to tacrolimus, aiding fertility in transplant patients.

Area of Science:

  • Immunology
  • Reproductive Medicine
  • Pharmacology

Background:

  • Sirolimus is a potent immunosuppressant used post-organ transplantation.
  • Previous studies indicate sirolimus can disrupt spermatogenesis via the stem cell factor/c-kit system.
  • Oligozoospermia, decreased testosterone, and increased gonadotropin levels have been observed in patients on sirolimus.

Observation:

  • A young renal transplant patient experienced azoospermia during sirolimus therapy.
  • Hormonal changes included decreased testosterone and increased gonadotropins.

Findings:

  • Spermatogenesis resumed after immunosuppression was switched from sirolimus to tacrolimus.
  • Significant sperm concentration was noted five months after sirolimus discontinuation.

Implications:

  • Sirolimus-induced testicular toxicity is a reversible side effect.
  • Discontinuation or avoidance of sirolimus is recommended for young men desiring paternity.
  • This highlights the importance of fertility preservation in transplant recipients.